Clinical Trial Update: Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating the efficacy, immunogenicity, and safety of Sanofi Pasteur's RSV vaccine in infants and toddlers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine (Sanofi Pasteur)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: RSV Immunisation | Phase 3 | Status: TERMINATED